SELPERCATINIB

Information current as at: 1 June 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Retevmo®
Form and strength:

Please search for and view the meeting agenda from the relevant meeting for more information

Submission sponsor:
ELI LILLY AUSTRALIA PTY LTD
Condition/indication:
(therapeutic use)
  • Medullary thyroid cancer (MTC)
Listing requested:
Please see meeting agenda for more information
Funding program:
Please see meeting agenda for more information
Request authority level:
Please see meeting agenda for more information
PBAC Submission type:
Change to existing listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
March 2026 PBAC meeting
Opportunity for consumer comment:
Open 19/11/2025 and close 21/01/2026 (see PBS Website)
PBAC meeting:
Held on 11/03/2026
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Exception applied
Lodgement of required documentation:
07/05/2026
Acceptance of complete documentation:
Accepted
Agreement to listing arrangements:
Commenced on 14/05/2026
Status:
Finalised
7Government processes:
Commenced on 20/05/2026
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:

Not yet published

Public Summary Document:
Not yet available
Case ID
a1181
Page last updated
31 May 2026
Return to the Medicine Status Listing
v.9.19